Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

The Use and Safety of TNF Inhibitors during Pregnancy in Women with Psoriasis: A Review

Research output: Contribution to journalReviewResearchpeer-review


  1. Correlation of MET-Receptor Overexpression with MET Gene Amplification and Patient Outcome in Malignant Mesothelioma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The collagen receptor uparap in malignant mesothelioma: A potential diagnostic marker and therapeutic target

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Effective clinical study recruitment of patients with atopic dermatitis through social media

    Research output: Contribution to journalLetterResearchpeer-review

  2. Airway hyperresponsiveness to inhaled mannitol identifies a cluster of non-eosinophilic asthma patients with high symptom burden

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Impact of white balance adjustment on evaluation of photographs of atopic dermatitis lesions

    Research output: Contribution to journalLetterResearchpeer-review

  4. Prevalence and characteristics of drug-drug interactions among hospitalised patients in the Capital Region of Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Psoriasis is a chronic immune-mediated inflammatory disease affecting women of childbearing potential. Biologic agents, notably Tumor Necrosis Factor inhibitors (TNFi), are the only current non-contraindicated systemic treatment option during pregnancy. TNFi comprised of complete immunoglobulin G (IgG) antibodies antibodies (adalimumab, golimumab, and infliximab) actively cross the placenta from the second trimester and are detectable in the child up to one year postpartum. Data on safety of TNFi are conflicting; however a trend towards drug-specific harm has been reported, with increased risk of congenital malformations and preterm birth. TNFi exposure may alter the immune system of the infant towards hypersensitivity and reduced response to intracellular infections. Confounding by indication should be considered, as chronic inflammatory disease itself may pose a risk of adverse pregnancy outcomes. The quality of the current evidence is very low and no studies specifically address TNFi safety in women with psoriasis. Nonetheless, risks associated with TNFi treatment must be balanced against the as-yet uncertain risk of adverse outcomes in infants born to women with severe psoriasis. We searched PubMed using Medical Subject Headings (MeSH) terms and identified relevant studies and guidelines. Herein, we present the current knowledge of the use and safety of TNFi during pregnancy in women with psoriasis.

Original languageEnglish
JournalInternational Journal of Molecular Sciences
Issue number5
Publication statusPublished - 3 May 2018

    Research areas

  • Animals, Dermatologic Agents/therapeutic use, Female, Humans, Immunoglobulin G/metabolism, Infant, Newborn, Inflammation/drug therapy, Nervous System Malformations/drug therapy, Pregnancy, Psoriasis/drug therapy

ID: 55741536